Serum levels of soluble CD30 in autologous peripheral blood stem cell transplantation

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 2, 2000, Pages 101-106

  Nagahama, Minori ^a   Nomura, Shosaku ^a   Katsura, Kaoruko ^a   Ozaki, Yoshio ^a   Yoshimura, Chie ^a   Kagawa, Hideo ^a   Fukuhara, Shirou ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Interferon ; Interleukin 4; Peripheral blood stem cell transplantation; Soluble CD30; Th2 type immune response

Indexed keywords

AUTOANTIGEN; CD30 ANTIGEN; CELL MARKER; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CELL MOTILITY; CLINICAL ARTICLE; COLONY FORMING UNIT; CYTOKINE PRODUCTION; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TH2 CELL;

EID: 0033959913     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00008480     Document Type: Article

References (43)

1. + cells by flow cytometry: application to the harvesting and transplantation of peripheral blood stem cells. In: Wunder E, Sovalat H, Henon P et al (eds) Hematopoietic stem cells: the Mulhouse manual. Alpha Medical Press, Dayton, pp 31-43
2. Bowen MA, Olen KJ, Cheng L, Avila D, Podack ER (1993) Functional effects of CD30 on a large granular lymphoma cell line, YT: inhibition of cytotoxicity,regulation of CD28 and IL-2R, and induction of homotypic aggregation. J Immunol 151:5896-5906
3. Brugger W, Bross KJ, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L (1992) Mobilization of peripheral blood progenitor cells by sequential administration of IL-3 and GM-CSF following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 79:1193-1200
4. Caligaris-Cappio F, Bertero MT, Converso M, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G (1995) Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 13:339-343
5. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG (1993) Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031-2035
6. Civin CL (1989) Summary of CD34 Cluster Workshop Section. In: Leukocyte typing. IV. Academic Press, London, pp 818-825
7. + T cells producing Th2-type cytokines. FASEB J 9:81-86
8. Del Prete G, De Carli M, D'Elios MM, Daniel KC, Almerigogna F, Alderson M, Smith CA, Thomas E, Romagnani S (1995b) CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 182:1655-1661
9. Del Prete G, Maggi E, Pizzolo G, Romagnani S (1995e) CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 16:76-80
10. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421-427
11. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S (1992) Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification in breast cancer. Blood 79:3036-3044
12. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor super-family as a tool for diagnosis and immunotherapy. Blood 85:1-14
13. Gause A, Pohl C, Tschiersch A, Da Costa L, Jung W, Diehl V, Hasenclever D, Pfreundschuh M (1991) Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77:1983-1988
14. + T cell involvement in the inflamed joints. Clin Exp Immunol 102:547-550
15. Goldman M, Druet P, Gleichmann E (1991) Th2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically induced autoimmunity. Immunol Today 12:223-227
16. Haas R, Ho AD, Bredthauer U, Cayeux S, Egerer G, Knauf W, Hunstein W (1990) Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18:94-98
17. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamanstein T (1989) Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. Partial characterisation of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157-162
18. Juttner CA, To LB, Ho J, Bardy PG, Dyson PG, Haylock DN, Kimber RJ (1988) Early lympho-hematopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc 20:40-42
19. + T cells. Immunol Today 12:392-395
20. Katsura K, Nomura S, Ohtani T, Matsumoto N, Shimizu T, Yamaguchi K, Kishimoto Y, Kitajima H, Fukuhara S (1998) Changes of immunological markers after autologous peripheral blood stem cell transfusion. J Cancer Res Clin Oncol 124:633-640
21. Kawano Y, Takaue Y, Saito S, Sato J, Shimizu T, Suzue T, Hirao A, Okamoto Y, Abe T, Watanabe T (1993) Granulocyte colony stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Blood 81:856-860
22. Kessinger A, Armitage JO (1991) The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77:211-213
23. Maggi E, Mazzetti M, Ravina A, Annuziato F, de Carli M, Piccinni MP, Manetti R, Carbonari M, Pesce AM, del Prete G (1994) Ability of HIV-1 to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 265:244-248
24. + T cell clone in human immunodeficiency virus (HIV) infection. J Exp Med 180:2407-2411
25. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cells clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348-2357
26. + anaplastic large-cell lymphoma. J Clin Oncol 13:1355-1360
27. Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, Stein H (1990) Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol 75:282-284
28. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandin G, Sinicco A, Raiteri R, Semenzato G, Stein H (1994) High serum levels of the soluble form CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 8:741-745
29. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB (1992) Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-304
30. Romagnani S (1994) Lymphokine production by human T cells in disease states. Annu Rev Immunol 12:227-257
31. Rubin LA (1990) The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum 33:1145-1148
32. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172-3177
33. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL (1992) Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthritis Rheum 35:1088-1096
34. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299:65-67
35. Sheridan WP, Begley CG, Juttner C, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644
36. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA, Jackson JD (1996) Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 17:101-109
37. Tepler I, Cannistra SA, Frei E, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Huntz H, Muto M (1993) Use of peripheral blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 11:1583-1591
38. Testa U, Martucci R, Rutella S, Scambia G, Sica S, Benedetti, Panici P, Pierelli L, Menichella G, Leone G, Mancuso S (1994) Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood 84:3532-3539
39. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQ, Dart GW, Horrath N, Davy ML (1992) Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogenetic transplants. Bone Marrow Transplant 9:277-284
40. Waldmann T (1993) The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 14:264-270
41. Wang G, Hansen H, Tatsis E, Csernok E, Lemke H, Gross WL (1997) High plasma levels of soluble form of CD30 activation molecule reflect dosease activity in patients woth Wegener's granulomatosis. Am J Med 102:517-523
42. Wolf RE, Brolsford WG (1988) Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 31:729-735
43. Zinzani PL, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S (1998) Clinical implications of stem levels of aoluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16:1532-1537